Abstract
To estimate the cost per responder (CPR) of currently approved biologic and subsequent entry biologic (SEB) agents in achieving reductions in the Psoriasis Area and Severity Index (PASI) score at the end of the induction period of therapy for adult patients with moderate-to-severe plaque psoriasis in Canada.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
